Sources we use and what each one is for
Every number on GLP1 Math traces back to a primary source. This page lists each one and the pages that rely on it, so a reader or reviewer can check our work in one place.
Last editorially updated: · By Jeff Schaeffer
Not medical advice. Talk to your prescriber and pharmacist. Confirm your prescribed dose, product, concentration, device, and instructions before using any calculation. This website cannot choose or change your treatment.
Prescribing information (the labels)
The official prescribing information for each brand product is the governing document for that product. We read it directly on DailyMed, the U.S. National Library of Medicine's database of current labels, rather than relying on summaries.
- Wegovy prescribing information is used on the semaglutide calculator, the dose schedule page and the missed-dose page for the labeled escalation checkpoints and the missed-dose wording. The injection and tablet sections are separate, and we only quote the injection section for injection questions.
- Ozempic prescribing information is used for pen presentations and the label's own missed-dose instruction. We do not treat Ozempic and Wegovy instructions as interchangeable.
- Zepbound prescribing information is used on the tirzepatide calculator and dose schedule for the labeled 2.5 mg steps and the vial presentation.
- Mounjaro prescribing information is used the same way for the Mounjaro pen presentations.
FDA safety communications
- FDA alert on dosing errors with compounded injectable semaglutide. This is why every calculator shows its formula and why we explain that the same milligram amount can mean very different syringe volumes at different concentrations. Most reported errors came from confusing units, milliliters and milligrams.
- FDA concerns about unapproved GLP-1 drugs used for weight loss. Used on the brand-versus-compounded page to explain what a compounded product label can and cannot tell you.
Clinical trials
- STEP 1 (Wilding and colleagues, 2021). The semaglutide 2.4 mg trial behind the weight-loss page. We report the published averages for the treatment and placebo groups and explain who was in the study and for how long. We never turn a trial average into a personal forecast.
- SURMOUNT-1 (Jastreboff and colleagues, 2022). The tirzepatide trial used the same way.
- Petri and colleagues, 2018. A pharmacokinetics paper we cite only to explain why weekly products are scheduled weekly, never to suggest changing a schedule.
Drug information for patients
- MedlinePlus drug pages for semaglutide and tirzepatide. Plain-language background from the National Library of Medicine, linked where a reader wants a second explanation in everyday words.
Advertising, analytics and privacy sources
Google's partner-sites policy, the AdSense required disclosures, My Ad Center and the Analytics opt-out page are linked from the privacy policy so readers can see exactly how advertising technology works on this site. Cloudflare's privacy policy covers hosting.
How we keep this list honest
When a label changes, we update the page that depends on it, change its "last editorially updated" date and note the change. If you find a page that cites something not on this list, or a number you cannot trace, tell us through the contact page and we will fix it or explain it.
Sources
- Wegovy prescribing information: injection and tablet sections are separate
- Ozempic injection prescribing information
- Zepbound prescribing information
- Mounjaro prescribing information
- FDA: dosing errors associated with compounded injectable semaglutide
- FDA concerns about unapproved GLP-1 drugs used for weight loss
- STEP 1 randomized trial: Wilding and colleagues, 2021 (PubMed)
- SURMOUNT-1 randomized trial: Jastreboff and colleagues, 2022 (PubMed)
- Petri and colleagues, 2018: population pharmacokinetics of once-weekly semaglutide
- MedlinePlus (U.S. National Library of Medicine): semaglutide injection drug information
- MedlinePlus (U.S. National Library of Medicine): tirzepatide injection drug information
- GLP1 Math editorial policy and correction standards